Health
COVAX to Facilitate Equal Access to COVID-19 Vaccine—WHO
By Adedapo Adesanya
The World Health Organisation (WHO) said the international community has established the COVAX Facility aimed at ensuring all countries have equal access to the coronavirus disease vaccines.
The head of the world health body, Mr Tedros Adhanom Ghebreyesus, said on Friday that there was an urgent need to address the financing gap to provide COVID-19 vaccines for everyone and everywhere.
In an appeal for stepped-up funding to support poorer countries, Mr Tedros said “this week, the United Kingdom began the rollout of a vaccine developed by pharmaceutical companies, Pfizer and BioNTech, and more nations are expected to follow suit very soon.”
Mr Tedros, speaking during his regular briefing from Geneva, Switzerland, further said: “To have safe and effective vaccines against a virus that was completely unknown to us only a year ago is an astounding scientific achievement.
“But an even greater achievement would be to ensure that all countries enjoy the benefits of science equitably.
“The international community has established a mechanism, known as the COVAX Facility, aimed at ensuring all countries will have equal access to any vaccines, once developed.”
Nearly 190 countries are participating, and the goal is to deliver two billion doses by the end of 2021.
Mr Tedros said there was an immediate funding gap of $4.3 billion to procure vaccines for the neediest countries.
“I urge donors to fill this gap quickly so that vaccines can be secured, lives can be saved and a truly global economic recovery is accelerated,” he stated.
The WHO chief also called on world leaders to translate political commitment for equitable vaccine access into action.
Meanwhile, the UN agency and its partners are helping countries to strengthen their supply chains in preparation for delivery.
Mr Tedros reported that nearly one billion doses of three vaccine candidates have already been secured, and further deals will be announced in the near future.
Evaluation of the first requests from countries eligible for assistance under the COVAX Facility is also underway.
WHO will soon be making its own determination as to whether some COVID-19 vaccines will be ready for rollout, a senior official said on Friday in response to a journalist’s question.
Several manufacturers have been submitting trial data to the WHO for emergency-use licensing.
Chief Scientist, Mr Soumya Swaminathan, said only those with Phase 3 clinical trial results would be considered.
“We started with the Pfizer dossier; we expect also to have the Moderna followed by the AstraZeneca dossiers examined in the next few weeks,” she said. “And we will be coming out with the decision whether it is receiving an emergency use license or not.”
Mrs Swaminathan added that WHO is working with the International Coalition for Medical Regulatory Agencies (ICMRA) “to speed up things further”. Several national regulators have also volunteered to assist with the assessments.
Her colleague, Mr Bruce Aylward, WHO Senior Adviser, explained that these processes were established to meet the goal of providing vaccines for all.
“We are indeed looking at these products though the WHO Emergency Use Listing Procedure,” he said.
“At the same time, we have an exceptional procedure in place where some products that are approved by what we call a stringent regulatory authority, can also be considered by the COVAX Facility, so there will be no barrier to the speed with which these products could potentially be used globally.”
Mrs Swaminathan recommended that countries will need to have national vaccination plans and related communications strategies in place.
It is important for authorities to explain the deployment process to citizens “because things are happening extremely fast and people are anxious for information”.
She said surveys indicate that most of the world’s population want a COVID-19 vaccine, “but at the same time, many do have questions concerning the process”
“Given that doses initially will be in limited supply, the public also needs to understand why priority will be given to frontline workers, the elderly and other at-risk groups.
“And the more open and transparent we can be, the more likely it is that people will have the trust and confidence and would not only want to take the vaccine but would also be patient and wait for their turn,” she said.
By Adedapo Adesanya
The Medical and Dental Practitioners Investigation Panel of the Medical and Dental Council of Nigeria (MDCN) has invoked its order of suspension against the Medical Director of Euracare Multi-Specialist Hospital, Dr Tosin Majekodunmi, and two others, after establishing a prima facie case of medical negligence against them in the management of the late Nkanu Adichie-Esege.
Nkanu, the son of renowned Nigerian author, Chimamanda Ngozi Adichie and Dr Ivara Esege, died on January 7, 2026, after receiving care at Atlantis Hospital and undergoing medical procedures at Euracare Multi-Specialist Hospital in Lagos. He was 21 months old.
Apart from the Medical Director at Euracare, the panel also suspended the anesthesiologist at the same hospital, Dr Titus Ogundare, as well as the Chief Medical Officer at Atlantis Pediatric Hospital, Dr Atinuke Uwajeh.
The trio were suspended from medical practice in Nigeria pending the determination of their case by the Medical and Dental Practitioners Disciplinary Tribunal.
A statement signed by the committee’s secretary, Dr Enejo Abdu, also disclosed it was determining if there is a prima facie case of professional misconduct against 10 other doctors.
These are Dr Adeseye Akinsete, Dr Chidinma Ohagwu, Dr Anthony Ajeh, Dr Amarachi Bayo, and Dr Nkechi Peji. Others are Dr Olaoye Oludare, Dr Agaja Oyinkansola, Dr Patricia Akintan, Dr Babatunde Bamgboye, and Dr Raji Faidat.
The panel, which also cleared eight other doctors, reached these decisions after considering the complaint against all 21 doctors and reviewing their counter-affidavits, including their oral depositions on oath.
It concluded its investigation at its 25th session held at Excel Hotel & Resort in Abuja on February 17 and 18, 2026.
The 21-month-old child, Nkanu Adichie-Esege, was initially admitted to Atlantis Hospital in Lagos for what was described as a worsening but initially mild illness.
While arrangements were being made to transfer him to Johns Hopkins Hospital in the United States, Atlantis referred him to Euracare for pre-flight diagnostic procedures, including an MRI, lumbar puncture, and insertion of a central line.
However, the child passed following the procedures.
His parents have alleged medical negligence and professional misconduct in connection with his death.
In a legal notice dated January 10, 2026, issued by the law firm led by Kemi Pinheiro (SAN), Ms Adichie and her husband accused Euracare, its anesthesiologist, and other attending medical personnel of breaching the duty of care owed to their son.
The notice stated that the child, born on March 25, 2024, was referred to Euracare on January 6, 2026, for diagnostic and preparatory procedures ahead of an emergency medical evacuation to the United States, where a specialist team was reportedly on standby.
The procedures reportedly included: Echocardiogram, Brain MRI, and insertion of a peripherally inserted central catheter.
Lumbar puncture, Intravenous sedation using propofol was administered.
The parents alleged that the child developed sudden and severe complications while being transported to the cardiac catheterisation laboratory after the MRI.
The development has raised worries and questions about the country’s healthcare.
By Adedapo Adesanya
The National Agency for the Control of AIDS (NACA) has announced that Nigeria would take delivery of Lenacapavir, a groundbreaking human immunodeficiency virus (HIV) prevention drug that has shown 100 per cent effectiveness in preventing the viral infection in clinical trials.
A short statement released by the Head of Public Relations for NACA, Mrs Toyin Aderibigbe, on Monday said the agency had secured regulatory approval from the National Agency for Food and Drug Administration and Control (NAFDAC).
HIV over time causes acquired immunodeficiency syndrome (AIDs), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.
Lenacapavir is an injectable treatment administered twice a year, making it a more convenient alternative to daily oral prevention drugs.
The drug is expected to be available in Nigeria and 119 other low- and middle-income countries at an affordable price of $40 per person annually, thanks to voluntary licensing agreements with generic manufacturers.
“The Government of Nigeria is advancing preparations for the introduction and rollout of Lenacapavir as Pre-Exposure Prophylaxis (PrEP).
“This is part of the government’s commitment to strengthen HIV prevention and accelerate progress toward epidemic control,” the statement read.
NACA listed some significant milestones achieved, including completion of landscape and readiness assessments across ten states: Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, FCT, Gombe, Kano, Kwara, and Lagos, alongside regulatory approval by NAFDAC.
“The commodities are expected in the country in March 2026,” NACA noted.
Nigeria has approximately 1.9 million people living with HIV, with a national prevalence of 1.3% among adults aged 15-49 years.
The country recorded 74,000 new HIV infections and 51,000 AIDS-related deaths in 2021.
The South-South zone has the highest HIV prevalence at 3.1%, while women aged 15-49 years are more than twice as likely to be living with HIV as men.
Daily oral PrEP has been available in Nigeria since 2016, but uptake varies. Adherence issues like pill fatigue, stigma, limited awareness, and inconsistent access have hindered wider use.
Newer PrEP options include injections that last two or six months, providing an alternative for those who prefer less frequent dosing and may overcome many barriers of daily oral use.
By Adedapo Adesanya
Members of the National Union of Food, Beverage and Tobacco Employees protested at the Lagos office of the National Agency for Food and Drug Administration and Control (NAFDAC), disrupting operations in reaction to the ban on sachet alcohol.
The protesting union members barricaded the agency’s premises in Isolo, meaning staff who arrived early to resume duty were forced to remain outside the complex.
Recall that NAFDAC has continued the ban on alcoholic beverages sold in sachets and PET bottles below 200 millilitres, despite calls from certain quarters, including the picketers.
The union is demanding the immediate unsealing of affected factories and production lines, warning that sustained enforcement of the policy could trigger significant economic consequences across the industry.
It is the second time this month that union members disrupted the Lagos NAFDAC office over what they described as the agency’s refusal to comply with an alleged federal government directive to suspend enforcement of the ban on the production and sale of alcoholic beverages in sachets.
The union claimed that directives had been issued by the Office of the Secretary to the Government of the Federation and the Office of the National Security Adviser, calling for the suspension of enforcement and the reopening of sealed production lines.
However, NAFDAC dismissed the claims, maintaining that it had not received any official instruction from the Federal Government to halt enforcement of the ban on sachet and PET-bottled alcohol.
Meanwhile, police officers were later seen at the NAFDAC Isolo premises, which dispersed the blockade to allow NAFDAC staff back into the premises.
Representatives of the Director-General of NAFDAC later engaged the protesting union in talks, but the meeting ended without resolution as demonstrators insisted their agitation would continue.
Union leaders presented their concerns during closed-door discussions with a director within the agency and the Special Assistant to the Director-General. However, no agreement was reached.
The protesters are urging NAFDAC to reconsider what they describe as the strict enforcement of the ban on sachet alcohol. Instead, they want the agency to focus on regulating access to such products, particularly by restricting sales to minors, while intensifying public enlightenment campaigns on responsible consumption.
Despite this, protesters say they will not stop until their demands are addressed.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn